Apricity, a London, UK-based leading virtual fertility clinic that has reimagined the fertility journey by combining technology and artificial intelligence, raised €17 million in Series B funding.
The round was led by MTIP, the Swiss healthtech investor, with participation from Iris Venture, a Barcelona-based specialist consumer fund.
The new funds will be used to accelerate Apricity’s growth in the UK, expand geographically (to Spain before the end of the year, followed by Germany and Italy), and further develop its technology, as it continues on its mission to become the leading fertility player in Europe. This includes expanding its at-home services to include at-home ultrasound scans in select areas.
Apricity’s tech team recently developed first-of-its-kind AI algorithms that identify the most suitable fertility treatment for patients and then determine the best embryo for selection through 3D reconstruction.
Apricity is the first company to develop 3D reconstruction technology for embryos to assist in fertility treatments. 2022 has seen Apricity double revenue, acquire women’s health app Woom, and grow its B2B offering, signing up employee benefits providers like AXA and Reward Gateway.
Company: Apricity Fertility UK Limited
Round: Series B
Funding Month: September 2022
Lead Investors: MTIP
Additional Investors: Iris Venture
Company Website: https://www.apricity.life/
Software Category: Fertility Treatments
About the Company: Launched in the UK in 2018, Apricity is a virtual fertility clinic that has reimagined the fertility journey by combining technology and artificial intelligence with personalized care and medical expertise. Its digital solution is designed to improve the fertility experience and maximize the chances of conception. It achieves this by providing access to world-class fertility advisors and a fully-customized treatment journey for patients, all easily navigated through a mobile app. Apricity’s mission is to help you create a life—and live yours.